D2 receptor variation and renal dysfunction
D2 receptor variation and renal dysfunction
批准号:
10564943
负责人:
Pedro A. Jose
金额:
$70.6万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-01-20 至 2027-12-31
关键词:
AccountingAdrenergic ReceptorAffectAgeAldosteroneAmishAngiotensinsAnimal ModelBlood PressureCardiovascular DiseasesCatecholaminesCellsCessation of lifeChinese populationChronic Kidney FailureCollectionConsumptionData SetDiabetes MellitusDiastolic blood pressureDietDietary AssessmentDopamineDopamine D2 ReceptorDouble-Blind MethodEnd stage renal failureEpigenetic ProcessEssential HypertensionEtiologyExcretory functionFailureGene ExpressionGenesGeneticHumanHypertensionImpairmentIncidenceIndividualInflammationInjury to KidneyInsulin ResistanceIntakeKidneyKidney DiseasesLipidsLipoproteinsMediatingMusNR4A2 geneNational Health and Nutrition Examination SurveyNon obesePatientsPlasmaPopulationPredispositionPrevalenceProximal Kidney TubulesRandomizedReceptor GeneReceptor InhibitionReceptor, Angiotensin, Type 1RecommendationRenal functionRenal tubule structureReninRenin-Angiotensin SystemResearchReservationsResistanceRiskRoleSodium ChlorideSprague-Dawley RatsSurveysSympathetic Nervous SystemTestingUrineVariantVascular Diseasesblood pressure elevationcardiovascular disorder riskcardiovascular risk factorcomorbiditygenetic varianthuman old age (65+)hypertension treatmenthypertensiveinflammatory markerkidney dysfunctionkidney fibrosismortalitynormotensiveobese personprecision medicineprematurepressurepreventreceptorreceptor expressionreceptor functionsalt intakesalt sensitiveselective expressiontranscription factorurinary
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Salt-sensitive (SS) individuals on high Na+ intake not only develop hypertension but also kidney
injury/ chronic kidney disease (CKD) and cardiovascular disease (CVD). A reduction in Na+
intake may prevent and treat hypertension, CVD, and CKD. However, low Na+ intake may not
always be beneficial in the treatment of hypertension or CVD. A low Na+ intake is associated
with increased risk of hypertension (i.e., inverse salt sensitivity (ISS), CVD, and death.
Hypertension and diabetes are the major causes of renal injury, accounting for up to 75% of
end-stage renal disease. However, hypertension may cause CKD only in the genetically
susceptible. In 13 of 16 studies in the GEO Dataset of CKD patients, dopamine type 2 receptor
(D2R) gene (DRD2) expression is lower in those with CKD than those without CKD. A decrease
in the expression or function of D2R, per se, or caused by DRD2 variants, increases renal
inflammation, renal fibrosis, and ISS. The mechanisms/genetics of ISS are not well understood.
Mice with global germline deletion of Drd2 (Drd2-/-) have SS hypertension and ISS. However,
mice with renal proximal tubule (RPT)-specific conditional deletion of Drd2 (Drd2cPT) have
increased blood pressure (BP) only when Na+ intake is decreased, a case of ISS. Sprague-
Dawley rats have ISS, related to an increase in the activity of the angiotensin type 1 receptor
(AT1R) and α1-adrenoceptors. About 15% of hypertensive subjects have ISS and some
associated with DRD2 rs6276/rs6277. Renal-selective expression of DRD2 variant rs6277 in
mice should increase BP and impair inhibition of renal Na+ transport and excretion. We will test
the overall hypothesis that DRD2/Drd2 is important in preventing ISS by mitigating overly
active renin-angiotensin and sympathetic nervous systems and the increase in RPT Na+
transport on a low Na+ diet. Specific Aim 1 will test the hypothesis that in Drd2-/- or Drd2cPT
mice, BP increases when Na+ intake is “low”, a case of ISS. The increase in BP in Drd2-/- or
Drd2cPT mice fed a low Na+ diet is caused by impaired D2R inhibition of RPT Na+ transport and
an increase in RPT Na+ transport caused by activation of both the renin-angioten-sin and
sympathetic nervous systems. In the long-term, renal function is decreased because of
unmitigated renal fibrosis. Specific Aim 2 will test the hypothesis that DRD2 variants,
rs6276/rs6277, decrease D2R expression that is dependent on the effects of the transcription
factors NR4a2 and miR4301. These studies are significant and important because they may
lead to the identification of the human population that would be adversely affected by the current
recommendation to decrease the Na+ intake in everyone.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lipid rafts, dopamine 1 receptor, and hypertension
-
批准号:9886774
-
项目类别:
-
资助金额:$64.24万
-
财政年份:2020
-
负责人:Pedro A. Jose
-
依托单位:
Lipid rafts, dopamine 1 receptor, and hypertension
-
批准号:10544330
-
项目类别:
-
资助金额:$64.24万
-
财政年份:2020
-
负责人:Pedro A. Jose
-
依托单位:
Lipid rafts, dopamine 1 receptor, and hypertension
-
批准号:10083735
-
项目类别:
-
资助金额:$64.24万
-
财政年份:2020
-
负责人:Pedro A. Jose
-
依托单位:
Lipid rafts, dopamine 1 receptor, and hypertension
-
批准号:10319571
-
项目类别:
-
资助金额:$64.24万
-
财政年份:2020
-
负责人:Pedro A. Jose
-
依托单位:
Ds receptor antioxidant activity and hypertension
-
批准号:8148031
-
项目类别:
-
资助金额:$35.93万
-
财政年份:2010
-
负责人:Pedro A. Jose
-
依托单位:
Dopamine-1 Receptor Defect in Hypertension
-
批准号:7921095
-
项目类别:
-
资助金额:$17.2万
-
财政年份:2009
-
负责人:Pedro A. Jose
-
依托单位:
GRK4 and development of salt sensitivity
-
批准号:8123257
-
项目类别:
-
资助金额:$43.0万
-
财政年份:2008
-
负责人:Pedro A. Jose
-
依托单位:
GRK4 and development of salt sensitivity
-
批准号:7658921
-
项目类别:
-
资助金额:$43.0万
-
财政年份:2008
-
负责人:Pedro A. Jose
-
依托单位:
GRK4 and development of salt sensitivity
-
批准号:7908700
-
项目类别:
-
资助金额:$43.0万
-
财政年份:2008
-
负责人:Pedro A. Jose
-
依托单位:
GRK4 and development of salt sensitivity
-
批准号:8266339
-
项目类别:
-
资助金额:$37.99万
-
财政年份:2008
-
负责人:Pedro A. Jose
-
依托单位:
D5 Receptor Antioxidant Activity and Hypertension
-
批准号:7218286
-
项目类别:
-
资助金额:$35.93万
-
财政年份:2006
-
负责人:Pedro A. Jose
-
依托单位:
Animal models of salt sensitivity: roles of GRK4 and sodium transporters on salt sensitivity
-
批准号:9283600
-
项目类别:
-
资助金额:$74.68万
-
财政年份:2004
-
负责人:Pedro A. Jose
-
依托单位:
GRK4 and D3R regulation of NHE3 and NCC expression
-
批准号:7778674
-
项目类别:
-
资助金额:$43.54万
-
财政年份:2004
-
负责人:Pedro A. Jose
-
依托单位:
D3, D1, AT1 Receptor Interaction--Genetic Hypertension
-
批准号:6781667
-
项目类别:
-
资助金额:$56.36万
-
财政年份:2003
-
负责人:Pedro A. Jose
-
依托单位:
D5 receptor antioxidant activity and hypertension
-
批准号:6656540
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2002
-
负责人:Pedro A. Jose
-
依托单位:
ONTOGENY OF DOPAMINE RECEPTOR/G-PROTEIN/EFFECTOR COUPLING
-
批准号:6346138
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2000
-
负责人:Pedro A. Jose
-
依托单位:
ONTOGENY OF DOPAMINE RECEPTOR/G-PROTEIN/EFFECTOR COUPLING
-
批准号:6201931
-
项目类别:
-
资助金额:$18.69万
-
财政年份:1999
-
负责人:Pedro A. Jose
-
依托单位:
ONTOGENY OF DOPAMINE RECEPTOR/G-PROTEIN/EFFECTOR COUPLING
-
批准号:6105772
-
项目类别:
-
资助金额:$18.69万
-
财政年份:1998
-
负责人:Pedro A. Jose
-
依托单位:
DOPAMINE-3 RECEPTOR SUBTYPE AND HYPERTENSION
-
批准号:6043980
-
项目类别:
-
资助金额:$22.07万
-
财政年份:1997
-
负责人:Pedro A. Jose
-
依托单位:
DOPAMINE-3 RECEPTOR SUBTYPE AND HYPERTENSION
-
批准号:2372962
-
项目类别:
-
资助金额:$21.01万
-
财政年份:1997
-
负责人:Pedro A. Jose
-
依托单位:
海外基金